关键词: 水飞蓟宾胶囊, 非诺贝特片, 非酒精性脂肪肝

Abstract: Objective To explore the clinical efficacy of silybin capsules combined with fenofibrate tablets in the treatment of non-alcoholic fatty liver.Methods One hundred and eighteen patients with non-alcoholic fatty liver treated in our hospital from March 2017 to May 2019 were selected as the research subjects and randomly divided into observation group and control group,with 59 cases in each group.Fifty-nine patients in the observation group were treated with silybin capsules and fenofibrate tablets,and 59 patients in the control group were treated with silybin capsules.After treatment,the clinical efficacy,liver function,blood glucose and blood uric acid,blood lipid,inflammation index,liver and spleen CT ratio,and safety index were used as the evaluation indicators.Results The clinical effective rate of the observation group was 96.61%,which was significantly higher than that of the control group (77.97%).The difference was statistically significant (P<0.05).The serum levels of ALT,AST and GGT in the observation group and the control group were significantly lower than those in the control group,and the observation group was significantly lower than the control group,the difference was significant (P<0.05).After treatment,the FBG,FINS and the control group were compared with the control group.The level of SUA was significantly different from that before treatment,and the observation group was significantly lower than the control group,with significant difference (P<0.05).The serum levels of TC,TG and LDL-C in the observation group and the control group were significantly decreased,and the observation group decreased greater than that of the control group.HDL-C was significantly increased,and the observation group was more significant than the control group.The serum IL-6,TNF-α and NF-κB in the observation group were compared with the control group.The decrease was significantly lower in the observation group than in the control group,and the difference was significant (P<0.05).The CT ratio of the liver and spleen in the observation group and the control group was significantly higher than that before the treatment,and the increase in the observation group was greater than that in the control group,and the difference was significant (P<0.05).There was no significant difference in adverse reactions between the observation group and the control group (P>0.05).Conclusion Silybin capsules combined with fenofibrate tablets in the treatment of non-alcoholic fatty liver can significantly improve clinical efficacy,enhance liver function,improve blood glucose,blood lipid and blood uric acid levels,reduce inflammation levels,and have good safety.It is worthy of clinical promotion.

Key words: Silybin capsules, Fenofibrate tablets, Nonalcoholic fatty liver